Orchestra BioMed Holdings, Inc. Operating Lease Right-of-Use Assets
Orchestra BioMed Holdings, Inc. (OBIO) had Operating Lease Right-of-Use Assets of $1.17 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-10
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.17M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.34M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.50M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.65M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.17M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $1.34M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.50M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $1.65M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.81M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.96M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.10M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.33M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.50M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $1.55M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.71M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.87M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.03M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $2.19M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |